Mohammed H Alqarni
Overview
Explore the profile of Mohammed H Alqarni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alam A, Alqarni M, Singh I, Foudah A, Upmanyu N, Balaha M
Curr Pharm Des
. 2025 Mar;
PMID: 40070330
Background: Anaplastic Lymphoma Kinase (ALK) is implicated in several cancers, including anaplastic large cell lymphoma, non-small cell lung cancer, and neuroblastoma. Targeted inhibition of ALK represents a promising therapeutic strategy....
2.
Alam P, Shakeel F, Alqarni M, Foudah A, Aljarba T, Bar F, et al.
BMC Chem
. 2025 Feb;
19(1):54.
PMID: 40022240
A novel sedative/hypnotic drug called suvorexant (SUV) is advised for treating insomnia. From a forensic standpoint, it is important medicine because of its sedative/hypnotic and depressing effects. There are no...
3.
Foudah A, Alqarni M, Alam A
ACS Omega
. 2025 Feb;
10(4):3427-3438.
PMID: 39926494
Ivosidenib (ISB) is an anticancer drug used to treat acute myeloid leukemia and cholangiocarcinoma. In order to determine and describe the degradation products (DPs) of ivosidenib, the International Conference on...
4.
Bar F, Alonazi R, Elekhnawy E, Samra R, Alqarni M, Badreldin H, et al.
J Ethnopharmacol
. 2024 Nov;
338(Pt 2):119089.
PMID: 39528120
Ethnopharmacological Relevance: Inflammation is a biological process in response to injury, resulting in altered blood flow, increased vascular permeability, tissue destruction, and the production of reactive oxygen species (ROS) and...
5.
Khalid M, Alqarni M, Foudah A
Mol Divers
. 2024 Oct;
PMID: 39470912
Proteolytic enzymes are closely associated with cancer and are important in different phases, including tumor growth, angiogenesis, and metastasis. Despite efforts to target matrix metalloproteases (MMPs), clinical trials have often...
6.
Alam A, Alqarni M, Alotaibi B, Khan F, Alam M, Alkhayl F, et al.
J Biomol Struct Dyn
. 2024 Sep;
:1-18.
PMID: 39295212
Tuberculosis (TB) is a global health challenge; therefore, there is an urgent requirement to develop a novel and more effective anti-TB therapeutic. This study targeted the isocitrate lyase (ICL) protein...
7.
Alam P, Shakeel F, Alshehri S, Iqbal M, Foudah A, Alqarni M, et al.
ACS Omega
. 2024 Jun;
9(21):23001-23012.
PMID: 38826538
The literature does not provide any "high-performance thin-layer chromatographic (HPTLC)" techniques for the determination of a novel antidiabetic medicine, ertugliflozin (ERZ). Additionally, there are not many environmentally friendly analytical methods...
8.
Naglah A, Almehizia A, Al-Wasidi A, Alharbi A, Alqarni M, Hassan A, et al.
Pharmaceuticals (Basel)
. 2024 May;
17(5).
PMID: 38794225
In this innovative research, we aim to reveal pyrazole-based Schiff bases as new multi-target agents. In this context, we re-synthesized three sets of pyrazole-based Schiff bases, -, -, and -,...
9.
Foudah A, Ayman Salkini M, Alqarni M, Alam A
Saudi J Biol Sci
. 2024 Feb;
31(4):103946.
PMID: 38384280
This study aimed to develop and optimize mangiferin-loaded solid lipid nanoparticles (MG-SLNs) using the microemulsion technique and ultrasonication. The MG-SLNs were composed of Labrafil M 2130 CS, MG, ethanol, Tween...
10.
Qian L, Khalid M, Alqarni M, Alshmmari S, Almoyad M, Wahab S, et al.
J Biomol Struct Dyn
. 2024 Jan;
43(7):3570-3584.
PMID: 38165437
Dihydrofolate reductase (DHFR) has gained significant attention in drug development, primarily due to marked distinctions in its active site among different species. DHFR plays a crucial role in both DNA...